{"id":8849,"date":"2026-05-20T18:06:00","date_gmt":"2026-05-20T16:06:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=aa8e5d01a90f955560c58cd58cf50a3c"},"modified":"2026-05-20T18:06:00","modified_gmt":"2026-05-20T16:06:00","slug":"kielements-detects-alzheimers-pathology-via-automated-phone-call-study-validates-speech-biomarker-across-five-european-cohorts","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=8849","title":{"rendered":"ki:elements Detects Alzheimer\u2019s Pathology via Automated Phone Call: Study Validates Speech Biomarker Across Five European Cohorts"},"content":{"rendered":"<p>SAARBR\u00dcCKEN, Germany--(BUSINESS WIRE)--New <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Falz-journals.onlinelibrary.wiley.com%2Fdoi%2F10.1002%2Falz.71462&amp;esheet=54538566&amp;newsitemid=20260520086790&amp;lan=en-US&amp;anchor=peer-reviewed+research+published&amp;index=1&amp;md5=88314ed6050bccce1dc80969e27a3633\" rel=\"nofollow\" shape=\"rect\">peer-reviewed research published<\/a> by ki:elements and the PROSPECT-AD consortium demonstrates that the company\u2019s Speech Biomarker for Cognition (SB-C) can reliably detect cognitive impairment and signal underlying Alzheimer\u2019s disease (AD) pathology through an AI voice agent that calls participants at home. The study, involving 736 participants across five independent cohorts in Spain, the UK, Germany and Sweden, is one of the largest and most geographically diverse validations of a speech-based digital cognitive assessment to date.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260520086790\/en\/2809840\/5\/Logo2-Ebony.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260520086790\/en\/2809840\/22\/Logo2-Ebony.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260520086790\/en\/2809840\/5\/Logo2-Ebony.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260520086790\/en\/2809840\/21\/Logo2-Ebony.jpg\" \/><\/a><p>\nThe research confirms that the SB-C consistently separated cognitive unimpaired individuals from those with mild cognitive impairment (MCI) or early dementia. Notably, the tool demonstrated a significant ability to classify Alzheimer\u2019s CSF biomarker status remotely. It identified amyloid-beta positivity with an AUC of up to 0.74 and phosphorylated tau 181 positivity with an AUC of up to 0.82.<\/p><p>\n<b>A Scalable Pre-Screen for Clinical Trials<\/b><\/p><p>\nRecruiting for AD clinical trials is traditionally one of the costliest phases of drug development, often requiring invasive and expensive procedures like lumbar punctures or PET scans to confirm eligibility. The SB-C offers the biopharma industry a validated first-pass enrichment layer, identifying individuals most likely to meet biomarker-positive eligibility criteria before committing to expensive invasive procedures.<\/p><ul class=\"bwlistdisc\">\n<li>\nFully Automated Delivery: The ki:elements Mili platform calls participants, administers the 10-minute assessment through a voice agent, and generates an automatic biomarker score.<\/li>\n<li>\nMultilingual Sensitivity: The SB-C proved effective across Spanish, Catalan, German, English, and Swedish language groups, utilizing 70 distinct speech features to index cognitive efficiency.<\/li>\n<li>\nRigorous Validation: The SB-C is validated following the Digital Medicine Society\u2019s V3 Framework and is currently deployed as a pre-screening tool in multiple AD clinical trials. It demonstrates strong convergent validity with clinical \u201cgold standards\u201d such as MMSE and PACC-5. By quantifying subtle functional speech changes, the platform provides a window into cognitive health that complements traditional paper tests.<\/li>\n<\/ul><p>\n\u201cWe\u2019ve known for years that one of the biggest hurdles in prevention trials is getting the right people into studies efficiently and at scale,\u201d said Prof Craig Ritchie, Professor of Brain health and Neurodegenerative Medicine at University of St Andrews and CEO and Founder of Scottish Brain Sciences, and co-author of the publication. \u201cIn this era of early-intervention Alzheimer\u2019s research, a validated digital cognitive assessment that correlates with AD pathology in multiple languages, without a clinician, opens up a generation of prevention trials that weren\u2019t feasible before.\u201d<\/p><p>\n\u201cThis study gives us real-world, multi-site evidence that a speech assessment can track with established cognitive measures and distinguish patients by their underlying pathology,\u201d said Dr. Alexandra K\u00f6nig, Chief Clinical Research Officer of ki:elements and corresponding author of the study. \u201cFor sponsors, this translates directly into faster, smarter recruitment, and a lower-burden tool for participants.\u201d<\/p><p>\n<b>About ki:elements<\/b><\/p><p>\nki:elements is a Germany-based digital health company specializing in AI-driven speech assessments. Its Mili platform and SB-C biomarker are validated, automated tools designed for global-scale deployment. The company partners with leading pharmaceutical companies and research institutions to accelerate early detection and decentralized clinical trial execution in Alzheimer\u2019s disease and other central nervous system conditions.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Contact<\/b><br\/>Sandya Iyer\n<br\/>Email: <a  href=\"mailto:sandya.iyer@ki-elements.de\" rel=\"nofollow\" shape=\"rect\">sandya.iyer@ki-elements.de<\/a><br\/>Website: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ki-elements.de&amp;esheet=54538566&amp;newsitemid=20260520086790&amp;lan=en-US&amp;anchor=www.ki-elements.de&amp;index=2&amp;md5=1993fe51dcaf221967c2a112e87cbf91\" rel=\"nofollow\" shape=\"rect\">www.ki-elements.de<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>SAARBR\u00dcCKEN, Germany&#8211;(BUSINESS WIRE)&#8211;New peer-reviewed research published by ki:elements and the PROSPECT-AD consortium demonstrates that the company\u2019s Speech Biomarker for Cognition (SB-C) can reliably detect cognitive impairment and signal underlyi&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8849","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/8849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8849"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/8849\/revisions"}],"predecessor-version":[{"id":8850,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/8849\/revisions\/8850"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}